PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
805.21%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.53%. Joel Greenblatt would see it as a clear outperformance relative to peers.
-1.20%
D&A shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a short-term earnings benefit if capacity is sufficient.
-144.47%
Deferred tax shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.
-31.19%
SBC declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
-216.50%
Working capital is shrinking yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage if sales remain robust.
-125.33%
AR shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage in working capital if sales do not drop.
-1216.66%
Inventory shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a working capital edge if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
61.39%
Growth of 61.39% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
-38.83%
Other non-cash items dropping yoy while Drug Manufacturers - Specialty & Generic median is 13.91%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
-170.95%
Negative CFO growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
38.81%
CapEx growth of 38.81% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
474.30%
Growth of 474.30% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss questions intangible or special projects explaining that difference.
85.28%
Investing flow of 85.28% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.
3.34%
Debt repayment growth of 3.34% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss wonders if expansions or a shift in capital structure drive that difference.
No Data
No Data available this quarter, please select a different quarter.
125.12%
Buyback growth of 125.12% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or higher yoy CFO enabling that difference.